Merck cancer drug Keytruda succeeds in late-stage trial

Share this post

U.S. drugmaker Merck & Co said on Wednesday its blockbuster cancer drug Keytruda met the main goal of a late-stage trial, of extending the lives of patients with cancers of the digestive tract.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply